FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225884047> ?p ?o ?g. }

• W4225884047 endingPage "e2022026" @default.
• W4225884047 startingPage "e2022026" @default.
• W4225884047 abstract "The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to high morbidity and mortality worldwide. Vaccination against SARS-CoV-2 is a leading strategy to change the course of the COVID-19 pandemic.Our aim was to investigate the efficacy and side effects of the Sinopharm vaccine in patients with hemoglobinopathies in Iran and the frequency of breakthrough infection after a full course of vaccination.A multicenter cross-sectional study of 434 patients with hemoglobinopathies (303 β-thalassemia major, 118 β-thalassemia intermedia, and 13 sickle-thalassemia) were conducted from March to July 2021 in IRAN. All patients have received the first dose of the China Sinopharm vaccine and received the second dose of the vaccine 28 days apar.Detection of immunity after vaccination was evaluated by commercial enzyme-linked immunosorbent assay (Pishtazteb ELISA commercial kit), including a surrogate virus neutralization test (sVNT), for detection of SARS-CoV-2 immunoglobulins (IgA, IgM, IgG), total neutralizing antibody (NAb).The mean age of patients was 35.0 ± 8.5 (from 18 to 70) years, and 55.6% were positive for the antibody. Overall, 48.2% of the studied population had at least one side effect after vaccination. The most frequent side effects were fever and chills, dizziness, and body pain. A total of 90 (20.7%) vaccinated patients developed breakthrough infections after two doses of Sinopharm vaccination. Disease severity was recorded, and it was classified as mild in 77.8%, moderate in 13.6%, and severe in 7.4% of patients. One 28-year-old woman with β-thalassemia major died eight days after diagnosing a breakthrough SARS-CoV-2 infection.No safety concerns were identified in patients who received two doses of the Sinopharm vaccine. Its efficacy was not optimal due to the lack of effect on new variations of the virus. However, our data show that it seems to be protective against the severity of COVID-19 infection in patients with hemoglobinopathies. The frequency of breakthrough infections after two doses of Sinopharm vaccination supports the evolving dynamic of SARS-CoV-2 variants requiring special challenge since such infection may represent a risk for vulnerable patients." @default.
• W4225884047 created "2022-05-05" @default.
• W4225884047 creator A5016350295 @default.
• W4225884047 creator A5017023713 @default.
• W4225884047 creator A5019411816 @default.
• W4225884047 creator A5026723131 @default.
• W4225884047 creator A5044158274 @default.
• W4225884047 creator A5058902392 @default.
• W4225884047 creator A5065908012 @default.
• W4225884047 creator A5069886748 @default.
• W4225884047 creator A5072205501 @default.
• W4225884047 creator A5076335356 @default.
• W4225884047 creator A5076821112 @default.
• W4225884047 date "2022-02-27" @default.
• W4225884047 modified "2023-10-10" @default.
• W4225884047 title "EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT" @default.
• W4225884047 cites W3006645647 @default.
• W4225884047 cites W3014721277 @default.
• W4225884047 cites W3024951159 @default.
• W4225884047 cites W3028010531 @default.
• W4225884047 cites W3032680518 @default.
• W4225884047 cites W3033580025 @default.
• W4225884047 cites W3085602091 @default.
• W4225884047 cites W3090717270 @default.
• W4225884047 cites W3092766467 @default.
• W4225884047 cites W3111341652 @default.
• W4225884047 cites W3120301726 @default.
• W4225884047 cites W3120504627 @default.
• W4225884047 cites W3129250309 @default.
• W4225884047 cites W3138032959 @default.
• W4225884047 cites W3141240025 @default.
• W4225884047 cites W3148644681 @default.
• W4225884047 cites W3153840436 @default.
• W4225884047 cites W3156509878 @default.
• W4225884047 cites W3158373340 @default.
• W4225884047 cites W3164415613 @default.
• W4225884047 cites W3165356560 @default.
• W4225884047 cites W3169082905 @default.
• W4225884047 cites W3178092981 @default.
• W4225884047 cites W3191428937 @default.
• W4225884047 cites W3206188191 @default.
• W4225884047 doi "https://doi.org/10.4084/mjhid.2022.026" @default.
• W4225884047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35444764" @default.
• W4225884047 hasPublicationYear "2022" @default.
• W4225884047 type Work @default.
• W4225884047 citedByCount "6" @default.
• W4225884047 countsByYear W42258840472022 @default.
• W4225884047 countsByYear W42258840472023 @default.
• W4225884047 crossrefType "journal-article" @default.
• W4225884047 hasAuthorship W4225884047A5016350295 @default.
• W4225884047 hasAuthorship W4225884047A5017023713 @default.
• W4225884047 hasAuthorship W4225884047A5019411816 @default.
• W4225884047 hasAuthorship W4225884047A5026723131 @default.
• W4225884047 hasAuthorship W4225884047A5044158274 @default.
• W4225884047 hasAuthorship W4225884047A5058902392 @default.
• W4225884047 hasAuthorship W4225884047A5065908012 @default.
• W4225884047 hasAuthorship W4225884047A5069886748 @default.
• W4225884047 hasAuthorship W4225884047A5072205501 @default.
• W4225884047 hasAuthorship W4225884047A5076335356 @default.
• W4225884047 hasAuthorship W4225884047A5076821112 @default.
• W4225884047 hasBestOaLocation W42258840471 @default.
• W4225884047 hasConcept C126322002 @default.
• W4225884047 hasConcept C159654299 @default.
• W4225884047 hasConcept C187212893 @default.
• W4225884047 hasConcept C203014093 @default.
• W4225884047 hasConcept C22070199 @default.
• W4225884047 hasConcept C2777799968 @default.
• W4225884047 hasConcept C2778594517 @default.
• W4225884047 hasConcept C2779134260 @default.
• W4225884047 hasConcept C2908647359 @default.
• W4225884047 hasConcept C3008058167 @default.
• W4225884047 hasConcept C524204448 @default.
• W4225884047 hasConcept C71924100 @default.
• W4225884047 hasConcept C89623803 @default.
• W4225884047 hasConcept C99454951 @default.
• W4225884047 hasConceptScore W4225884047C126322002 @default.
• W4225884047 hasConceptScore W4225884047C159654299 @default.
• W4225884047 hasConceptScore W4225884047C187212893 @default.
• W4225884047 hasConceptScore W4225884047C203014093 @default.
• W4225884047 hasConceptScore W4225884047C22070199 @default.
• W4225884047 hasConceptScore W4225884047C2777799968 @default.
• W4225884047 hasConceptScore W4225884047C2778594517 @default.
• W4225884047 hasConceptScore W4225884047C2779134260 @default.
• W4225884047 hasConceptScore W4225884047C2908647359 @default.
• W4225884047 hasConceptScore W4225884047C3008058167 @default.
• W4225884047 hasConceptScore W4225884047C524204448 @default.
• W4225884047 hasConceptScore W4225884047C71924100 @default.
• W4225884047 hasConceptScore W4225884047C89623803 @default.
• W4225884047 hasConceptScore W4225884047C99454951 @default.
• W4225884047 hasIssue "1" @default.
• W4225884047 hasLocation W42258840471 @default.
• W4225884047 hasLocation W42258840472 @default.
• W4225884047 hasLocation W42258840473 @default.
• W4225884047 hasLocation W42258840474 @default.
• W4225884047 hasOpenAccess W4225884047 @default.
• W4225884047 hasPrimaryLocation W42258840471 @default.
• W4225884047 hasRelatedWork W2038518800 @default.
• W4225884047 hasRelatedWork W2050936608 @default.

• next